Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138709 | 0.81 | MKNK1 (0.56) | CFTRFGFR1EGLN1MKNK1MKNK2 | |
| SCHEMBL17802570 | 0.78 | CFTR (0.61) | CFTRFGFR1MAP4K4 | |
| SCHEMBL26479837 | 0.77 | EGLN1 (0.55) | FGFR1EGLN1 | |
| SCHEMBL5112478 | 0.75 | MAPT (0.47) | FGFR1EGLN1HPGD | |
| SCHEMBL17815681 | 0.74 | CFTR (0.79) | CFTRFGFR1MAP4K4 | |
| SCHEMBL29547715 | 0.73 | FGFR1 (0.61) | CFTRFGFR1MKNK1MKNK2 | |
| SCHEMBL29829801 | 0.73 | PARP1 (0.54) | CFTRFGFR1EGLN1PIK3R2 | |
| SCHEMBL29547628 | 0.71 | FGFR1 (0.55) | CFTRFGFR1MKNK1MKNK2 | |
| SCHEMBL20604030 | 0.71 | FGFR1 (0.74) | FGFR1MKNK1MKNK2 | |
| SCHEMBL29993159 | 0.71 | FGFR1 (0.74) | FGFR1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | CFTR 1/4885FGFR1 832/4885EGLN1 523/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | CFTR 1/4885FGFR1 832/4885EGLN1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.